Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Cantor Fitzgerald
Moodys
Johnson and Johnson
Harvard Business School

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 7,217,519

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,217,519
Title:Histoplasma capsulatum chitin synthase sequences and their use for detection of Histoplasma capsulatum and histoplasmosis
Abstract: The present invention describes Histoplasmosis capsulatum chitin synthase nucleic acid and protein sequences as reagents for the detection of H. capsulatum infection. Specifically, the invention describes intron sequences from the H. capsulatum chitin synthase gene which can be used for hybridization-based and PCR-based detection of H. capsulatum infection. In another embodiment, assays for H. capsulatum chitin synthase 2 polypeptide and/or mRNA used as a diagnostic test for H. capsulatum infection and/or histoplasmosis. Also described is the differentiation of H. capsulatum from Blastomyces dermititidis based on detection of intron 1 sequences specific to H. capsulatum chitin synthase 2. The present invention also comprises the production of H. capsulatum strains lacking functional chitin synthase 2 as a means to produce H. capsulatum having reduced pathogenicity.
Inventor(s): Johnson; Clayton H. (Little Rock, AR), McEwen; Joan E. (Little Rock, AR)
Assignee: The Board of Trustees of the University of Arkansas (Little Rock, AR)
Application Number:10/718,955
Patent Claims:see list of patent claims

Details for Patent 7,217,519

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up The Board of Trustees of the University of Arkansas (Little Rock, AR) 2022-11-21 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up The Board of Trustees of the University of Arkansas (Little Rock, AR) 2022-11-21 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up The Board of Trustees of the University of Arkansas (Little Rock, AR) 2022-11-21 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Moodys
Covington
Boehringer Ingelheim
Queensland Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.